All In Biotech

Drug Trial Radar · NCT06021574

A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody

A Single Center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of a Novel Recombinant Humanized Anti Interleukin-6 Receptor Monoclonal Antibody in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jun 28, 2019

Primary completion

Jan 6, 2020

Study completion Jan 6, 2020

Sponsor

Lead sponsor
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing VDJBio Co., LTD.
First posted
Sep 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to study the tolerability, safety, pharmacokinetics and immunogenicity of investigational drug in healthy subjects. The main questions it aims to answer are: * Safety and tolerability of investigational drug. * pharmacokinetics and immunogenicity of investigational drug. Participants will receive a single intravenous administration of investigational drug or placebo. Blood samples are collected at specified time points.

Conditions

  • Healthy

Interventions

  • VDJ001Drug

    a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. adverse eventsTime frame: up to 57 days
  2. Pharmacokinetics-AUC0-tTime frame: up to 57 days
  3. Pharmacokinetics-AUC0-infTime frame: up to 57 days
  4. Pharmacokinetics-CmaxTime frame: up to 57 days
  5. Pharmacokinetics-TmaxTime frame: up to 57 days
  6. Pharmacokinetics-t1/2Time frame: up to 57 days
  7. Pharmacokinetics-VzTime frame: up to 57 days
  8. Pharmacokinetics-CLzTime frame: up to 57 days
  9. Pharmacokinetics- λzTime frame: up to 57 days
  10. Pharmacokinetics-MRT0-tTime frame: up to 57 days
  11. Pharmacokinetics-MRT0-infTime frame: up to 57 days
  12. Anti-Drug antibody (ADA)Time frame: up to 57 days
  13. Neutralizing antibodies (Nab)Time frame: up to 57 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the Affliated Hospital of Qingdao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.